ANNE E EVINS

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Placebo-controlled trial of glycine added to clozapine in schizophrenia
    A E Evins
    The Psychotic Disorders Unit of the Massachusetts General Hospital, Boston, MA, USA
    Am J Psychiatry 157:826-8. 2000
  2. ncbi Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
  3. ncbi A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders
    A Eden Evins
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 28:660-6. 2008
  4. ncbi Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
  5. ncbi A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania
    A Eden Evins
    Department of Psychiatry of the Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Bipolar Disord 8:75-80. 2006
  6. ncbi A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females
    A Eden Evins
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:597-602. 2011
  7. ncbi Inositol augmentation of lithium or valproate for bipolar depression
    A Eden Evins
    Harvard Bipolar Research Program and Department of Psychiatry of the Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Bipolar Disord 8:168-74. 2006
  8. ncbi A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
  9. ncbi A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia
    A E Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Nicotine Tob Res 3:397-403. 2001
  10. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005

Research Grants

  1. Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia
    A Eden Evins; Fiscal Year: 2010
  2. NICOTINE AND SMOKING CESSATION IN SCHIZOPHRENIA
    A Evins; Fiscal Year: 2005
  3. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2006
  4. Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia
    A Evins; Fiscal Year: 2007
  5. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2009

Detail Information

Publications47

  1. ncbi Placebo-controlled trial of glycine added to clozapine in schizophrenia
    A E Evins
    The Psychotic Disorders Unit of the Massachusetts General Hospital, Boston, MA, USA
    Am J Psychiatry 157:826-8. 2000
    ..The purpose of this study was to evaluate the effects of high-dose oral glycine on positive and negative symptoms and cognitive function when added to clozapine in adults with schizophrenia...
  2. ncbi Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia
    A Eden Evins
    Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1184-90. 2005
    ....
  3. ncbi A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders
    A Eden Evins
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 28:660-6. 2008
    ..Given the high abstinence rate achieved with CBT plus NRT, a ceiling effect related to the high level of intervention received by all subjects may have prevented an adequate test of bupropion...
  4. ncbi Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychiatry 65:307-11; quiz 452-3. 2004
    ....
  5. ncbi A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania
    A Eden Evins
    Department of Psychiatry of the Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Bipolar Disord 8:75-80. 2006
    ..In an open trial, donepezil augmentation was associated with improvement in manic symptoms in 9 of 11 subjects...
  6. ncbi A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females
    A Eden Evins
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:597-602. 2011
    ....
  7. ncbi Inositol augmentation of lithium or valproate for bipolar depression
    A Eden Evins
    Harvard Bipolar Research Program and Department of Psychiatry of the Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Bipolar Disord 8:168-74. 2006
    ..Up to half of patients do not respond adequately to currently approved treatments. This study evaluated the efficacy of adjunctive inositol for bipolar depression...
  8. ncbi A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
    J Clin Psychopharmacol 27:380-6. 2007
    ....
  9. ncbi A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia
    A E Evins
    Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Nicotine Tob Res 3:397-403. 2001
    ..These data suggest that bupropion SR, 150 mg/day, combined with CBT, may facilitate smoking reduction in patients with schizophrenia while stabilizing psychiatric symptoms during a quit attempt...
  10. ncbi A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia
    A Eden Evins
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
    J Clin Psychopharmacol 25:218-25. 2005
    ..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation...
  11. ncbi High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
    Michael A Dyer
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Schizophr Res 102:88-95. 2008
    ..In summary, galantamine treatment, at a dose of 32 mg/day, was well tolerated but was not effective as an adjunctive treatment for cognitive deficits in stable nonsmokers with schizophrenia...
  12. ncbi The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
    Ruth S Barr
    The Schizophrenia Program of the Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 33:480-90. 2008
    ..These results confirm previous findings that a single dose of nicotine improves attention and suggest that nicotine may specifically improve response inhibition in nonsmokers with schizophrenia...
  13. ncbi A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence
    Ruth S Barr
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 63:1061-5. 2008
    ..Accumulated evidence suggests that nicotine may increase appetitive responding for nondrug incentives in the environment...
  14. ncbi Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial
    Oliver Freudenreich
    Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    J Clin Psychiatry 70:1674-80. 2009
    ..Clozapine-induced sedation can worsen cognition and impair social and occupational functioning...
  15. ncbi Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia
    Lindsay E Jubelt
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Psychopharmacology (Berl) 199:89-98. 2008
    ..Nicotinic agonists may improve attention and memory in humans and may ameliorate some cognitive deficits associated with neuropsychiatric disorders such as schizophrenia...
  16. ncbi Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 159:140-6. 2008
    ..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...
  17. ncbi Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychopharmacol 29:165-9. 2009
    ..087). The addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant improvements on several outcome measures that predict risk for medical morbidity...
  18. ncbi Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight
    Oliver Freudenreich
    MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:1372-6. 2004
    ....
  19. ncbi Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study
    David C Henderson
    Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1116-21. 2005
    ..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease...
  20. ncbi A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men
    Tsafrir Loebl
    Center for Addiction Medicine of the Department of Psychiatry and the Biostatistics Center of Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 69:480-6. 2008
    ..We tested the efficacy of a long-acting, injectable preparation of risperidone on cocaine use in active cocaine users...
  21. ncbi Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Hum Psychopharmacol 24:225-32. 2009
    ....
  22. ncbi A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  23. ncbi Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence
    Amy C Janes
    Brain Imaging Center, McLean Hospital, Belmont, MA 02478, USA
    Exp Clin Psychopharmacol 17:365-73. 2009
    ..In some brain regions, fMRI smoking cue reactivity is increased during extended smoking abstinence in comparison to the prequit state, which may contribute to persisting relapse vulnerability...
  24. ncbi D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
    A Eden Evins
    Harvard Medical School and the Schizophrenia Research Program of the Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 56:19-23. 2002
    ..The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia...
  25. ncbi Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 51:493-7. 2002
    ....
  26. ncbi Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  27. ncbi Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders
    A Eden Evins
    Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 64:9-14. 2003
    ..Some new antiepileptic medications such as lamotrigine, gabapentin, topiramate, oxcarbazepine, tiagabine, and zonisamide are beginning to be used to treat bipolar disorder...
  28. ncbi Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study
    Donald C Goff
    Massachusetts General Hospital, Psychiatry Department, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
    Schizophr Res 106:320-7. 2008
    ..The objective of this exploratory study was to assess whether once-weekly dosing with d-cycloserine will produce persistent improvements in negative symptoms and cognition...
  29. ncbi A placebo-controlled study of sildenafil effects on cognition in schizophrenia
    Donald C Goff
    Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
    Psychopharmacology (Berl) 202:411-7. 2009
    ..In addition, neuronal nitric oxide synthase, another component of the NMDA/nitric oxide/cGMP intracellular pathway, has been reported to be dysregulated in schizophrenia patients...
  30. ncbi Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence
    Amy C Janes
    Brain Imaging Center McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Biol Psychiatry 67:722-9. 2010
    ..We hypothesized that functional magnetic resonance imaging (fMRI) reactivity to smoking-related cues, measured before a quit attempt, could identify smokers with heightened relapse vulnerability...
  31. ncbi Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study
    Marc J Kaufman
    Brain Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, United States
    Psychiatry Res 173:143-9. 2009
    ....
  32. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  33. ncbi Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness
    Diego A Pizzagalli
    Department of Psychology, Harvard University, 1220 William James Hall, 33 Kirkland Street, Cambridge, MA 02138, USA
    Psychopharmacology (Berl) 196:221-32. 2008
    ..Animal studies have emphasized the role of phasic dopamine (DA) signaling in reward-related learning, but these processes remain largely unexplored in humans...
  34. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia
    Richard L Kradin
    Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 351:2741-9. 2004
  35. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  36. ncbi Neural substrates of attentional bias for smoking-related cues: an FMRI study
    Amy C Janes
    Brain Imaging Center, McLean Hospital, Belmont, MA 02478, USA
    Neuropsychopharmacology 35:2339-45. 2010
    ..Treatments capable of inhibiting shifts to drug cue-induced memories and internal states may lead to personalized tobacco dependence treatment for smokers with high attentional bias to smoking-related stimuli...
  37. ncbi Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
    Oliver Freudenreich
    MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
    Psychopharmacology (Berl) 181:358-63. 2005
    ..A donepezil add-on strategy might make sense in selected schizophrenia cases where a pathological process is known to affect cholinergic neurons (e.g., history of head injury or comorbid dementia)...
  38. ncbi Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
    Ann Clin Psychiatry 22:33-42. 2010
    ..The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia...
  39. ncbi Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants
    Roy H Perlis
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Arch Gen Psychiatry 65:882-92. 2008
    ....
  40. ncbi Sexual functioning, psychopathology and quality of life in patients with schizophrenia
    Xiaoduo Fan
    Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    Schizophr Res 94:119-27. 2007
    ..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents...
  41. ncbi Smoking cessation in patients with psychiatric disorders
    Alan J Gelenberg
    Department of Psychiatry, University of Arizona, Tucson, USA
    J Clin Psychiatry 68:1404-10. 2007
  42. ncbi Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Psychiatr Pract 15:251-61. 2009
    ....
  43. ncbi The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychother Psychosom 72:115-27. 2003
    ..If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders...
  44. ncbi Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis
    David C Henderson
    Schizophrenia Program, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:789-97. 2006
    ..Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism...
  45. ncbi Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse?
    Nikos Makris
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuron 60:174-88. 2008
    ..These observations suggest that brain structure abnormalities in addicts are related in part to drug use and in part to predisposition toward addiction...
  46. ncbi Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)
    Oliver Freudenreich
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    Psychiatry Res 176:99-102. 2010
    ....
  47. ncbi Varenicline treatment for smokers with schizophrenia: a case series
    A Eden Evins
    J Clin Psychiatry 69:1016. 2008

Research Grants9

  1. Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia
    A Eden Evins; Fiscal Year: 2010
    ..Participants will then discontinue study medications and enter a 3-month follow up. The primary outcome measure will be 7-day point prevalence abstinence rate at 12 months in the intervention vs. placebo groups. ..
  2. NICOTINE AND SMOKING CESSATION IN SCHIZOPHRENIA
    A Evins; Fiscal Year: 2005
    ....
  3. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2006
    ....
  4. Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia
    A Evins; Fiscal Year: 2007
    ..Participants will then discontinue study medications and enter a 3-month follow up. The primary outcome measure will be 7-day point prevalence abstinence rate at 12 months in the intervention vs. placebo groups. ..
  5. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2009
    ....